Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02819726 · ClinicalTrials.gov registry record · Phase 1
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
A Phase 1 study, sponsored by Archigen Biotech Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 294
- Enrollment target
NCT02819726 is a Phase 1 study that has completed, run by Archigen Biotech Limited. The registered enrollment target is 294 participants.
The verdict
NCT02819726, a Phase 1 study, has completed, sponsored by Archigen Biotech Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 294 participants
- Enrollment target
Study Summary
A randomised, double blind, parallel group, multicentre study yo compare the pharmacokinetics, pharmacokinetics, safety and efficacy of SAIT101 versus MabThera® versus Rituxan® in patients with rheumatoid arthritis.
Interventions
- BIOLOGICAL SAIT101
- BIOLOGICAL Rituxan
- BIOLOGICAL MabThera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2016-10-11 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02819726
The ClinicalTrials.gov registry entry for NCT02819726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Archigen Biotech Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SAIT101 is the first listed.
NCT02819726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02819726 about?
NCT02819726 is a clinical study titled "PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis". A randomised, double blind, parallel group, multicentre study yo compare the pharmacokinetics, pharmacokinetics, safety and efficacy of SAIT101 versus MabThera® versus Rituxan® in patients with rheumatoid arthritis.
What is the current status of trial NCT02819726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 294 participants. The study started on 2016-10-11. Estimated completion is 2018-11-07.
What interventions are being tested in trial NCT02819726?
The interventions under investigation include: SAIT101 (BIOLOGICAL), Rituxan (BIOLOGICAL), MabThera (BIOLOGICAL).
Who is sponsoring clinical trial NCT02819726?
This trial is sponsored by Archigen Biotech Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.